• Recombinant Mouse IFN-γ for Antigen Presentation

  2026-08-17

  Recombinant Mouse IFN-γ is a research-grade Interferon gamma preparation for murine antiviral, immunomodulatory, macrophage, TH1, and antigen-presentation workflows. Product benchmarks include greater than 95% SDS-PAGE purity, endotoxin below 1 EU/µg, and an antiviral-assay EC50 of 0.3–0.9 ng/mL under the stated L-929 and encephalomyocarditis virus conditions.

• BRD4–RAC1 Co-targeting in Breast Cancer

  2026-08-17

  The reference study identifies combined BRD4 and RAC1 inhibition as a subtype-sensitive strategy that suppresses breast cancer growth, migration, stemness, and tumorigenesis. Its mechanistic contribution is the connection of BRD4–RAC1 signaling to the c-MYC–G9a–FTH1 axis and HDAC1-associated histone regulation, providing a framework for testing epigenetic dependencies in cancer models.

• ETV5, EZH2, and Hepatocellular Carcinoma Progression

  2026-08-16

  This pan-cancer study identifies ETV5 as a prognostic transcription factor linked to epigenetic regulation and demonstrates a functional relationship between ETV5, EZH2 activity, and hepatocellular carcinoma progression. Its integrated computational and experimental design suggests that ETV5 may help explain adverse prognosis and reduced response to the EZH2 inhibitor GSK126 in selected tumors.

• SAR405: A Precision Vps34 Inhibitor Workflow

  2026-08-15

  SAR405 provides a selective way to separate Vps34-dependent phosphatidylinositol 3-phosphate production from upstream energy-stress signaling. This practical workflow combines dose finding, GFP-FYVE or GFP-LC3 imaging, lysosome readouts, and AMPK–ULK1-aware controls for autophagy inhibition, vesicle trafficking modulation, and cancer research.

• Chuanxiong Cortex, Pith, and CHD Mechanisms

  2026-08-14

  The reference study combines SPME-GC×GC-MS, network pharmacology, and molecular docking to distinguish the volatile chemical and predicted therapeutic profiles of Chuanxiong cortex and pith in coronary heart disease research. Its main contribution is to show that anatomically distinct rhizome regions should not be treated as chemically interchangeable, while also providing a hypothesis-generating workflow for prioritizing compounds and targets.

• EZH2 Inhibition in HPV-Associated Cervical Cancer

  2026-08-14

  The reference study evaluates EPZ-6438 and ZLD1039 as EZH2 inhibitors in HPV-positive and HPV-negative cervical cancer models, combining proliferation, apoptosis, cell-cycle, molecular, and exploratory in vivo readouts. Its main contribution is the identification of stronger EPZ-6438 activity in HPV-positive cells and the association of EZH2 inhibition with reduced HPV16 E6/E7 expression, restoration of p53 and Rb, and epithelial-state markers.

• Caspase 3/7 Link Autophagy to DNA Damage Responses

  2026-08-13

  The reference study identifies CASP3 and CASP7 as active regulators of cytoprotective autophagy and DNA damage signaling during non-lethal stress in human breast cancer cells. Its genetic, biochemical, and rescue experiments show that caspase activity can support stress adaptation rather than simply execute apoptosis, while revealing synthetic lethality with BRCA1 loss.

• Tubastatin A: HDAC6 Inhibitor Workflow Guide

  2026-08-13

  Build more informative HDAC6 inhibition experiments with Tubastatin A, from DMSO stock preparation and target-engagement assays to cell-death pathway profiling. A porcine cardiac-arrest study adds a practical translational model for connecting microtubule regulation with pyroptosis, necroptosis, and myocardial injury.

• M344: Reliable HDAC Assay Workflows

  2026-08-12

  This scenario-driven guide explains how M344 (SKU A4105) can improve experimental planning for viability, proliferation, cytotoxicity, apoptosis, and differentiation studies. It connects documented potency, cell-model evidence, formulation guidance, and vendor-selection criteria to practical laboratory decisions.

• AZ505: A Translational Framework for SMYD2 Inhibition

  2026-08-12

  A mechanistic and translational guide to using AZ505, a potent and selective SMYD2 inhibitor, across epigenetic regulation research, cancer biology, and fibrosis models.

• SP2509 Workflows for LSD1-Targeted AML Research

  2026-08-11

  SP2509 combines potent LSD1 inhibition with a practical workflow for studying histone-state changes, apoptosis induction in AML cells, and differentiation-associated phenotypes. This guide connects biochemical validation, chromatin assays, combination studies, and troubleshooting while keeping evidence from acute myeloid leukemia models distinct from hypothesis-generating breast cancer research.

• Rocilinostat (ACY-1215) Experimental Workflow Guide

  2026-08-11

  Rocilinostat (ACY-1215) enables selective HDAC6 interrogation in multiple myeloma viability, apoptosis, and proteasome-inhibitor combination assays. This workflow also shows how its acetylated α-tubulin readout can support carefully controlled, hypothesis-generating studies of primary cilia and neural progenitor biology.

• PD98059: ERK Causality in Oxidative Injury

  2026-08-10

  PD98059 is a reversible MEK inhibitor for dissecting ERK-driven cell-cycle, apoptosis, and oxidative-injury mechanisms. This article develops a causality-focused assay framework grounded in cyclophosphamide hepatotoxicity research rather than repeating a conventional product overview.

• 10074-G5 Workflow for c-Myc Inhibition

  2026-08-09

  10074-G5 is a practical small-molecule c-Myc inhibitor for connecting c-Myc/Max dimerization with apoptosis, cell cycle arrest, and transcriptional network changes. This workflow adapts the compound for cancer research while showing how the MYC/TERT/NFκB findings in esophageal adenocarcinoma can guide assay selection without overstating translational validation.

• Epigenetic Silencing in Multi-Transcript Gene Circuits

  2026-08-08

  The reference study shows that CRISPR-Cas9 integration can produce heterogeneous expression of multi-transcript genetic circuits through chromatin accessibility and epigenetic silencing rather than obvious sequence alteration. Its combination of reporter phenotyping, pharmacological perturbation, and ATAC-seq provides a practical framework for diagnosing unstable circuit function in mammalian cells.

8041 records 8/537 page Previous Next First page 上5页 678910 下5页 Last page